December 8th 2023
The phase 3 LEAP-001 trial did not meet its primary end points of overall survival and progression-free survival.
December 5th 2023
The FDA has granted priority review to the supplemental biologics application of mirvetuximab soravtansin-gynx for the treatment of patients with platinum-resistant ovarian cancer.
November 28th 2023
Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.
November 14th 2023
The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.
Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
Targeted Agent Demonstrates Strong Activity in Uterine Serous Carcinoma
"Adavosertib demonstrated promising preliminary clinical activity in patients with unselected uterine serous cancer."
PARP Inhibitor Costs Give Patients With Ovarian Cancer Financial Toxicity
Ross F. Harrison, MD, discusses the out-of-pocket costs for patients with ovarian cancer receiving PARP inhibitor treatment.
Dostarlimab on the Road to Progress in dMMR Endometrial Cancer
“There are limited treatment options for women with advanced or recurrent endometrial cancer, and prognosis of these patients is poor. The results observed in the GARNET trial indicate the potential of dostarlimab to offer a new treatment option for women with this challenging disease.”
Novel Monoclonal Antibody Demonstrates Clinical Activity in Gynecologic Malignancies
"We are seeing clinically meaningful monotherapy activity of DKN-01 in heavily pre-treated endometrial cancer and carcinosarcoma populations, including a complete response, a partial response, and durable tumor reductions in many patients. In combination with paclitaxel, DKN-01 is generating durable responses and disease control in paclitaxel-experienced patients."
FDA Approves cobas HPV Test for Measurement of Cervical Cancer Risk in Women with High-Risk HPV
"The approval of our HPV test for the cobas 6800 and 8800 Systems enables molecular laboratories to achieve the efficiency and scale they need to meet the demands of high-volume cervical screening programs..."
Cost-Effectiveness of Frontline PARP Inhibitor Maintenance in Advanced Ovarian Cancer
Olaparib Matches Chemotherapy Outcomes in Platinum-Sensitive Recurrent Ovarian Cancer
Treatment with olaparib demonstrated similar outcomes to standard-of-care chemotherapy treatment in patients with BRCA wild-type, platinum-sensitive, recurrent epithelial ovarian cancer in the phase II CLIO study. As such, olaparib failed to demonstrate a significant improvement in survival over chemotherapy.
Niraparib Grabs Regulatory Attention in China for Treatment of Advanced Ovarian Cancer
Niraparib was granted Priority Review in China as a maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy, by the National Medical Products Administration.
Extended Maintenance Therapy in Ovarian Cancer
Understanding GOG-0218 & ICON7 Trials
Maintenance Therapy in Stage IIIc Ovarian Cancer
Treatment Options in Stage IIIc Ovarian Cancer
Germline Testing in Stage IIIc Ovarian Cancer
Presentation of Stage IIIc Ovarian Cancer
A 59-Year Old Woman With Stage IIIC Ovarian Cancer
Veliparib Spotlighted for Antitumor Efficacy in Ovarian Cancer
In the phase III VELIA trial, the addition of veliparib to frontline induction chemotherapy expanded the number of complete responses and CA-125 responses in patients with high-grade serous ovarian cancer compared with chemotherapy alone, according to results from an exploratory analysis.
Vigil Immunotherapy Prolongs RFS as Frontline Maintenance Treatment in Ovarian Cancer
Relapse-free survival was prolonged in patients with stage III/IV ovarian cancer who received frontline maintenance treatment with Vigil immunotherapy compared with placebo. This was especially true for patients with BRCA1/2 wild-type disease, according to results from the phase II VITAL study.
Frontline Niraparib Plus Bevacizumab for Advanced Ovarian Cancer Yields Promising Activity
Frontline niraparib in addition to bevacizumab as maintenance demonstrated impressive clinical activity in patients with advanced ovarian cancer who achieved either a complete or partial response to frontline platinum-based chemotherapy with bevacizumab, according to the phase II OVARIO trial.
Analyses of Frontline Niraparib Maintenance Demonstrate Positive Patient-Reported Outcomes in Ovarian Cancer
Following its success in the phase III PRIMA study, frontline niraparib maintenance demonstrated positive patient-reported outcomes, as well as met biomarker-defined and other secondary endpoints, according to 3 analyses to be reported as part of the Society of Gynecologic Oncology 2020 Annual Meeting.
FDA Grants Fast Track Designation to Balstilimab in Metastatic Cervical Cancer
The FDA has granted Fast Track designation to balstilimab, an investigational anti-PD-1 agent for the treatment of patients with cervical cancer, based on comprehensive data that suggest balstilimab can fill an unmet medical need in the space, Agenus, Inc announced in a press release. In light of the new designation, the company now plans to submit 2 Biologic License Applications in 2020, for this indication and the other for the combination of balstilimab and zalifrelimab in metastatic cervical cancer.
FDA Grants Pembrolizumab Priority Review for TMB-High Tumors
The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Effects of Para-aortic Lymph Node Metastases on Endometrial Cancer Survival
Carrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors
An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.
COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care
A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.
Investigational Anti-Cancer Agent Elicits Responses in Platinum-Resistant Ovarian Cancer
Treatment with an investigational targeted anti-cancer gene-therapy agent, VB-111, in addition to paclitaxel met the pre-specified efficacy criterion of an absolute percentage advantage of 10% or higher CA-125 response rate in patients with platinum-resistant ovarian cancer, according to results from the planned interim analysis of the phase III OVAL trial.<br />
Data Demonstrate Efficacy of 3 PARP Inhibitors in Ovarian Cancer
Angeles Alvarez Secord, MD, discusses the key takeaways on the role of PARP inhibitors in ovarian cancer, based on data presented for 3 PARP inhibitors, olaparib, rucaparib, and niraparib.
Cetuximab Plus Chemotherapy Worsens Survival in Resectable Colorectal Liver Metastases
Despite demonstrating improvement in overall survival as treatment of patients with advanced inoperable metastatic colorectal cancer, cetuximab plus chemotherapy led to significantly worse survival for patients with operable colorectal liver metastases in the perioperative setting, according to findings from randomized phase III clinical trial.
South Carolina Oncology Practice Continues Cautious Operation Amidst the COVID-19 Pandemic
In an interview with Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br />
Benefit of PARP Inhibitors May Extend to Certain Tumors With IDH Mutations
Patients harboring IDH1/2 muta­tions may receive benefit by the use of PARP inhibitors, with investigators initi­ating clinical trials in patients across multiple different tumor types to determine the efficacy of this strategy.
Pembrolizumab Monotherapy Elicits Responses in Patients With Advanced Rare Cancers
Treatment with pembrolizumab demonstrated antitumor activity along with tolerable toxicity in patients with 4 different rare and hard-to-treat malignancies, according to results from a phase II study led by The University of Texas MD Anderson Cancer Center researchers and published in the Journal for ImmunoTherapy of Cancer.
2 Clarke Drive Cranbury, NJ 08512